McKesson (MCK) Set to Post Earnings on Wednesday

McKesson (NYSE:MCK) is projected to post its Q2 2027 results after the market closes on Wednesday, November 4th. Analysts expect McKesson to post earnings of $10.72 per share and revenue of $109.90 billion for the quarter. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Individuals can check the company’s upcoming Q2 2027 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. The business had revenue of $105.38 billion during the quarter, compared to the consensus estimate of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The company’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.26 EPS. On average, analysts expect McKesson to post $44.71 EPS for the current fiscal year and $49.99 EPS for the next fiscal year.

McKesson Stock Up 0.7%

MCK opened at $1,001.05 on Tuesday. The stock has a market cap of $116.71 billion, a PE ratio of 26.79, a PEG ratio of 1.91 and a beta of 0.30. The business has a 50 day moving average of $925.32 and a 200-day moving average of $863.78. McKesson has a 52 week low of $723.68 and a 52 week high of $1,030.27.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, December 1st. McKesson’s payout ratio is 10.06%.

Insider Buying and Selling

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of McKesson stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the completion of the sale, the chief accounting officer owned 521 shares of the company’s stock, valued at approximately $464,445.45. This trade represents a 17.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 800 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $995.80, for a total value of $796,640.00. Following the completion of the transaction, the executive vice president owned 5,423 shares of the company’s stock, valued at $5,400,223.40. This represents a 12.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,212 shares of company stock worth $1,164,182 in the last three months. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Evercore reaffirmed an “outperform” rating and issued a $950.00 target price (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. UBS Group increased their price target on shares of McKesson from $1,080.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Friday, October 16th. Wall Street Zen raised shares of McKesson from a “hold” rating to a “buy” rating in a research report on Saturday, October 17th. Morgan Stanley set a $977.00 price objective on shares of McKesson in a research note on Tuesday, October 6th. Finally, Bank of America boosted their price objective on shares of McKesson from $950.00 to $1,050.00 in a research note on Thursday, August 6th. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $997.12.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.